Anixa Biosciences Inc Shares Rise 37.79% From The Lows – But Will They Continue?

In last trading session, Anixa Biosciences Inc (NASDAQ:ANIX) saw 0.47 million shares changing hands with its beta currently measuring 0.85. Company’s recent per share price level of $3.44 trading at -$0.18 or -4.97% at ring of the bell on the day assigns it a market valuation of $110.70M. That closing price of ANIX’s stock is at a discount of -49.13% from its 52-week high price of $5.13 and is indicating a premium of 37.79% from its 52-week low price of $2.14. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.13 million shares which gives us an average trading volume of 67.27K if we extend that period to 3-months.

For Anixa Biosciences Inc (ANIX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.08 in the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Anixa Biosciences Inc (NASDAQ:ANIX) trade information

Upright in the red during last session for losing -4.97%, in the last five days ANIX remained trading in the red while hitting it’s week-highest on Friday, 11/08/24 when the stock touched $3.44 price level, adding 18.1% to its value on the day. Anixa Biosciences Inc’s shares saw a change of -11.34% in year-to-date performance and have moved -6.01% in past 5-day. Anixa Biosciences Inc (NASDAQ:ANIX) showed a performance of 14.29% in past 30-days. Number of shares sold short was 0.59 million shares which calculate 12.35 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 7.5 to the stock, which implies a rise of 54.13% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 8. It follows that stock’s current price would drop -103.49% in reaching the projected high whereas dropping to the targeted low would mean a loss of -103.49% for stock’s current value.

Anixa Biosciences Inc (ANIX) estimates and forecasts

Statistics highlight that Anixa Biosciences Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 14.67% of value to its shares in past 6 months, showing an annual growth rate of -31.25% while that of industry is 16.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 16.79% during past 5 years.

Anixa Biosciences Inc (NASDAQ:ANIX)’s Major holders

Insiders are in possession of 5.05% of company’s total shares while institution are holding 17.46 percent of that, with stock having share float percentage of 18.39%. Investors also watch the number of corporate investors in a company very closely, which is 17.46% institutions for Anixa Biosciences Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at ANIX for having 1.39 million shares of worth $3.08 million. And as of 2024-06-30, it was holding 4.3646 of the company’s outstanding shares.

The second largest institutional holder is D.A. DAVIDSON & CO., which was holding about 0.74 million shares on 2024-06-30. The number of shares represents firm’s hold over 2.3075 of outstanding shares, having a total worth of $1.63 million.